|
1
|
Davies L and Welch HG: Current thyroid
cancer trends in the United States. JAMA Otolaryngol Head Neck
Surg. 140:317–322. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Roman BR, Morris LG and Davies L: The
thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol
Diabetes Obes. 24:332–336. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cabanillas ME, McFadden DG and Durante C:
Thyroid cancer. Lancet. 388:2783–2795. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Luo L, Xia L, Zha B, Zuo C, Deng D, Chen
M, Hu L, He Y, Dai F, Wu J, et al: miR-335-5p targeting ICAM-1
inhibits invasion and metastasis of thyroid cancer cells. Biomed
Pharmacother. 106:983–990. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Li R, Teng X, Zhu H, Han T and Liu Q:
MiR-4500 regulates PLXNC1 and inhibits papillary thyroid cancer
progression. Horm Cancer. 10:150–160. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Liu F, Lou K, Zhao X, Zhang J, Chen W,
Qian Y, Zhao Y, Zhu Y and Zhang Y: miR-214 regulates papillary
thyroid carcinoma cell proliferation and metastasis by targeting
PSMD10. Int J Mol Med. 42:3027–3036. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Minna E, Romeo P, Dugo M, De Cecco L,
Todoerti K, Pilotti S, Perrone F, Seregni E, Agnelli L, Neri A, et
al: miR-451a is underexpressed and targets AKT/mTOR pathway in
papillary thyroid carcinoma. Oncotarget. 7:12731–12747.
2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Qiu Z, Li H, Wang J and Sun C: miR-146a
and miR-146b in the diagnosis and prognosis of papillary thyroid
carcinoma. Oncol Rep. 38:2735–2740. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Condello V, Torregrossa L, Sartori C,
Denaro M, Poma AM, Piaggi P, Valerio L, Materazzi G, Elisei R,
Vitti P and Basolo F: mRNA and miRNA expression profiling of
follicular variant of papillary thyroid carcinoma with and without
distant metastases. Mol Cell Endocrinol. 479:93–102.
2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhu HM, Jiang XS, Li HZ, Qian LX, Du MY,
Lu ZW, Wu J, Tian XK, Fei Q, He X and Yin L: miR-184 inhibits tumor
invasion, migration and metastasis in nasopharyngeal carcinoma by
targeting Notch2. Cell Physiol Biochem. 49:1564–1576.
2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wang JX, Gao J, Ding SL, Wang K, Jiao JQ,
Wang Y, Sun T, Zhou LY, Long B, Zhang XJ, et al: Oxidative
modification of miR-184 enables it to target Bcl-xL and Bcl-w. Mol
Cell. 59:50–61. 2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zheng X, Carstens JL, Kim J, Scheible M,
Kaye J, Sugimoto H, Wu CC, LeBleu VS and Kalluri R:
Epithelial-to-mesenchymal transition is dispensable for metastasis
but induces chemoresistance in pancreatic cancer. Nature.
527:525–530. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Da C, Wu K, Yue C, Bai P, Wang R, Wang G,
Zhao M, Lv Y and Hou P: N-cadherin promotes thyroid tumorigenesis
through modulating major signaling pathways. Oncotarget.
8:8131–8142. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lv N, Shan Z, Gao Y, Guan H, Fan C, Wang H
and Teng W: Twist1 regulates the epithelial-mesenchymal transition
via the NF-κB pathway in papillary thyroid carcinoma. Endocrine.
51:469–477. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Rodriguez IP, Chakravarthi BVSK and Varambally
S: UALCAN: A portal for facilitating tumor subgroup gene expression
and survival analyses. Neoplasia. 19:649–658. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhang XJ, Su YR, Liu D, Xu DB, Zeng MS and
Chen WK: Thymosin beta 10 correlates with lymph node metastases of
papillary thyroid carcinoma. J Surg Res. 192:487–493.
2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Xiao R, Shen S, Yu Y, Pan Q, Kuang R and
Huang H: TMSB10 promotes migration and invasion of cancer cells and
is a novel prognostic marker for renal cell carcinoma. Int J Clin
Exp Pathol. 12:305–312. 2019.PubMed/NCBI
|
|
18
|
Zhang X, Ren D, Guo L, Wang L, Wu S, Lin
C, Ye L, Zhu J, Li J, Song L, et al: Thymosin beta 10 is a key
regulator of tumorigenesis and metastasis and a novel serum marker
in breast cancer. Breast Cancer Res. 19(15)2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Tang J, Kong D, Cui Q, Wang K, Zhang D,
Yuan Q, Liao X, Gong Y and Wu G: Bioinformatic analysis and
identification of potential prognostic microRNAs and mRNAs in
thyroid cancer. PeerJ. 6(e4674)2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Xu Y, Chen J, Yang Z and Xu L:
Identification of RNA expression profiles in thyroid cancer to
construct a competing endogenous RNA (ceRNA) Network of mRNAs, Long
noncoding RNAs (lncRNAs), and microRNAs (miRNAs). Med Sci Monit.
25:1140–1154. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lee SM, Na YK, Hong HS, Jang EJ, Yoon GS,
Park JY and Kim DS: Hypomethylation of the thymosin β(10) gene is
not associated with its overexpression in non-small cell lung
cancer. Mol Cells. 32:343–348. 2011.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Song C, Su Z and Guo J: Thymosin β10 is
overexpressed and associated with unfavorable prognosis in
hepatocellular carcinoma. Biosci Rep.
39(BSR20182355)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Wang B, Wang Z, Zhang T and Yang G:
Overexpression of thymosin β10 correlates with disease progression
and poor prognosis in bladder cancer. Exp Ther Med. 18:3759–3766.
2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Paolillo M and Schinelli S: Extracellular
matrix alterations in metastatic processes. Int J Mol Sci.
20(4947)2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Pradella D, Naro C, Sette C and Ghigna C:
EMT and stemness: Flexible processes tuned by alternative splicing
in development and cancer progression. Mol Cancer.
16(8)2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Calangiu CM, Simionescu CE, Stepan AE,
Cernea D, Zăvoi RE and Mărgăritescu C: The expression of CK19,
vimentin and E-cadherin in differentiated thyroid carcinomas. Rom J
Morphol Embryol. 55:919–925. 2014.PubMed/NCBI
|
|
28
|
Morillo-Bernal J, Fernandez LP and
Santisteban P: FOXE1 regulates migration and invasion in thyroid
cancer cells and targets ZEB1. Endocr Relat Cancer. 27:137–151.
2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Xia W and Jie W:
ZEB1-AS1/miR-133a-3p/LPAR3/EGFR axis promotes the progression of
thyroid cancer by regulating PI3K/AKT/mTOR pathway. Cancer Cell
Int. 20(94)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Li T, Zhao N, Lu J, Zhu Q, Liu X, Hao F
and Jiao X: Epigallocatechin gallate (EGCG) suppresses
epithelial-Mesenchymal transition (EMT) and invasion in anaplastic
thyroid carcinoma cells through blocking of TGF-β1/Smad signaling
pathways. Bioengineered. 10:282–291. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Werner TA, Forster CM, Dizdar L, Verde PE,
Raba K, Schott M, Knoefel WT and Krieg A: CXCR4/CXCR7/CXCL12 axis
promotes an invasive phenotype in medullary thyroid carcinoma. Br J
Cancer. 117:1837–1845. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Yang Z, Yu W, Huang R, Ye M and Min Z:
SIRT6/HIF-1α axis promotes papillary thyroid cancer progression by
inducing epithelial-mesenchymal transition. Cancer Cell Int.
19(17)2019.PubMed/NCBI View Article : Google Scholar
|
